According to a recent study, there is an indication of minor added benefit for adult patients with moderate COPD (grade II) using the fixed-dose combination aclidinium bromide/formoterol.

For adults with grade III and fewer than 2 exacerbations (flare-ups) per year, there is proof of considerable added benefit versus the comparator therapy, according to the German Institute for Quality and Efficiency in Health Care (IQWiG), which conducted the study.

However, no conclusions can be drawn on greater or lesser benefit for more severely ill patients from the data presented.